These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16931569)

  • 41. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients.
    Zaman A; Rosen HR; Ingram K; Corless CL; Oh E; Smith K
    Am J Med; 2007 Mar; 120(3):280.e9-14. PubMed ID: 17349453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
    Maor Y; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P
    Haemophilia; 2006 Jul; 12(4):372-9. PubMed ID: 16834736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
    Myers RP; Ratziu V; Imbert-Bismut F; Charlotte F; Poynard T;
    Am J Gastroenterol; 2002 Sep; 97(9):2419-25. PubMed ID: 12358267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
    Castéra L; Sebastiani G; Le Bail B; de Lédinghen V; Couzigou P; Alberti A
    J Hepatol; 2010 Feb; 52(2):191-8. PubMed ID: 20006397
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.
    Yakoob R; Bozom IA; Thandassery RB; Rahman MO; Derbala MF; Mohannadi MJ; John AK; Sharma M; Wani H; Kaabi SA
    Ann Gastroenterol; 2015; 28(2):265-270. PubMed ID: 25830472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.
    Rossi E; Adams L; Prins A; Bulsara M; de Boer B; Garas G; MacQuillan G; Speers D; Jeffrey G
    Clin Chem; 2003 Mar; 49(3):450-4. PubMed ID: 12600957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
    Munteanu M; Pais R; Peta V; Deckmyn O; Moussalli J; Ngo Y; Rudler M; Lebray P; Charlotte F; Thibault V; Lucidarme O; Ngo A; Imbert-Bismut F; Housset C; Thabut D; Ratziu V; Poynard T;
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1117-1127. PubMed ID: 30334263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
    Morra R; Munteanu M; Bedossa P; Dargere D; Janneau JL; Paradis V; Ratziu V; Charlotte F; Thibault V; Imbert-Bismut F; Poynard T
    Aliment Pharmacol Ther; 2007 Sep; 26(6):847-58. PubMed ID: 17767469
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
    Park MS; Kim BK; Cheong JY; Kim DJ; Park JY; Kim DY; Ahn SH; Han KH; Chon CY; Kim SU
    PLoS One; 2013; 8(2):e55759. PubMed ID: 23405210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C.
    Cardoso AC; Carvalho-Filho RJ; Stern C; Dipumpo A; Giuily N; Ripault MP; Asselah T; Boyer N; Lada O; Castelnau C; Martinot-Peignoux M; Valla DC; Bedossa P; Marcellin P
    Liver Int; 2012 Apr; 32(4):612-21. PubMed ID: 22103765
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
    Boursier J; Bertrais S; Oberti F; Gallois Y; Fouchard-Hubert I; Rousselet MC; Zarski JP; Calès P
    BMC Gastroenterol; 2011 Nov; 11():132. PubMed ID: 22129438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies.
    Poynard T; Ngo Y; Munteanu M; Thabut D; Massard J; Moussalli J; Varaud A; Benhamou Y; Ratziu V
    Antivir Ther; 2010; 15(4):617-31. PubMed ID: 20587855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients.
    Omran D; Zayed RA; Nabeel MM; Mobarak L; Zakaria Z; Farid A; Hassany M; Saif S; Mostafa M; Saad OK; Yosry A
    Viral Immunol; 2018 May; 31(4):315-320. PubMed ID: 29630460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
    de Lédinghen V; Vergniol J; Barthe C; Foucher J; Chermak F; Le Bail B; Merrouche W; Bernard PH
    Aliment Pharmacol Ther; 2013 May; 37(10):979-88. PubMed ID: 23557139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
    Colletta C; Smirne C; Fabris C; Toniutto P; Rapetti R; Minisini R; Pirisi M
    Hepatology; 2005 Oct; 42(4):838-45. PubMed ID: 16121354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
    Myers RP; Tainturier MH; Ratziu V; Piton A; Thibault V; Imbert-Bismut F; Messous D; Charlotte F; Di Martino V; Benhamou Y; Poynard T
    J Hepatol; 2003 Aug; 39(2):222-30. PubMed ID: 12873819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of liver fibrosis: noninvasive means.
    Poynard T; Morra R; Ingiliz P; Imbert-Bismut F; Thabut D; Messous D; Munteanu M; Massard J; Benhamou Y; Ratziu V
    Saudi J Gastroenterol; 2008 Oct; 14(4):163-73. PubMed ID: 19568532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
    Sebastiani G; Castera L; Halfon P; Pol S; Mangia A; Di Marco V; Pirisi M; Voiculescu M; Bourliere M; Alberti A
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1202-16. PubMed ID: 21981787
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
    Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
    AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
    Stibbe KJ; Verveer C; Francke J; Hansen BE; Zondervan PE; Kuipers EJ; de Knegt RJ; van Vuuren AJ
    Scand J Gastroenterol; 2011 Jul; 46(7-8):962-72. PubMed ID: 21623677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.